News | July 08, 2007

CCNY, Memorial Sloan-Kettering Receive $1.36 Million Breast Cancer Research Grant

July 9, 2007 – The U.S. Army Medical Research and Materiel Command Breast Cancer Research Program has granted $1.36 million over four years to The City College of New York (CCNY) and Memorial Sloan-Kettering Cancer Center (MSKCC) for the evaluation of near-infrared light’s use to detect and diagnose breast cancer and assess tumor aggressiveness.
“Our goal is to use near-infrared light to get images of tumors and try to determine whether they are malignant or benign,” said Swapan Gayen, professor of Physics and principal investigator for the project. “We also want to be able to distinguish between slow and fast-growing breast tumors, and assess how rapidly tumors are growing.”
Near-infrared light allows researchers to change the wavelength and color of the light to detect different types of molecules found in the breast, such as hemoglobin, lipids, proteins and water. “It’s essentially molecular spectroscopy, and it provides diagnostic potential,” said Gayen. “MRI can provide similar information, but it is more expensive and not readily available.”
According to CCNY, Gayen and his colleagues plan to construct a model breast with known tumors using tissue samples to determine if it can obtain an image, locate tumors and distinguish between tumor and normal tissue. They will then compare their findings to results from X-rays and MRI.
In order to measure the rate of tumor growth, the researchers will implant different types of known tumors in animal models and monitor their progress using conventional methods and near-infrared light, with the hope of conducting in vivo research in the future.
For more information: www.

Related Content

Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Siemens Healthineers Showcases syngo Virtual Cockpit for More Flexible Workforce Management
News | Teleradiology | November 25, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...